High loading dose of clopidogrel in patients undergoing percutaneous coronary intervention
Journal Title: Przewodnik Lekarza - Year 2005, Vol 78, Issue 6
Abstract
In recent years in Poland a great development of interventional treatment of patients with acute coronary syndromes (ACS) has been seen. Since the publication of the CURE study, on the treatment of ACS patients, and the analysis of a subgroup treated with percutaneous coronary intervention (PCI) a loading dose of 300 mg of clopidogrel has become a routine practice. The later studies though, revealed that such a dose, given immediately before or during the intervention is not sufficient to reduce significantly the risk of periprocedural ischemic complications. One of the possible solutions may be to delay the intervention for several hours after clopidogrel pretreatment. Since in the most of ACS patients a clear benefit of immediate intervention has been demonstrated, the new studies on the higher dosing were started. Those studies, including low- as well as high-risk patients undergoing PCI in stable angina or in non-ST elevation ACS revealed a significant advantage of a loading dose of 600 mg, with acceptable risk of bleeding complications. Although none such a study (with a dose of 600 mg) has been performed yet in patients with ST elevation ACS, the two recent studies have demonstrated significant advantage of clopidogrel 300 mg over placebo, and there is no reason to claim that the higher dose will be not beneficial in this high-risk population. In the last ESC PCI guidelines there is a recommendation IC that a clopidogrel loading dose of 600 mg should be preferred in patients, both with and without ST-elevation ACS if pretreatment with the drug can not be initiated at least 6 hours prior to intervention. Given the efficacy and safety of the higher dose of clopidogrel, we are convinced that in the „real world” setting, the best option could be a prehospital pretreatment with 600 mg of clopidogrel in all ACS patients.
Authors and Affiliations
Stefan Grajek, Maciej Lesiak
Keywords
Related Articles
- EP ID EP139081
- DOI -
- Views 97
- Downloads 0
Familial hipercholesterolemia - pathogenesis, clinic and management
Familial hypercholesterolemia (FH) is a genetic disorder, which occurs in two forms, as homozygous FH with frequency 1/1 000 000 persons or heterozygous FH with frequency 1/500 persons, what makes about 78 000 cases in...
Risk factors of cardiovascular events in primary care patients
This work presents epidemiological data from survey called Standard of Primary Cardiac Care (SPOK) realized among national program of prevention and treatment of cardiovascular diseases (POLKARD). The study was run on...
Nadciśnienie tętnicze u osób w podeszłym wieku
Częstość nadciśnienia tętniczego wzrasta z wiekiem i istotnie zwiększa ryzyko powikłań sercowo-naczyniowych. Wartości docelowe terapii nadciśnienia tętniczego są takie same, jak u młodszych chorych (poniżej 140/90 mmHg...
When paroxysmal atrial fibrillation in patients with celebral stroke requires cardivention
Incidence of atrial fibrillation as well as cerebral stroke increases with age. One of the most serious consequences of atrial fibrillation is the occurrence of cerebral embolism. In the treatment of patients with paro...
Beta-blokery w leczeniu niewydolności sercaBadanie CIBIS III
Niewydolność serca jest ważnym problemem opieki zdrowotnej. W Europie liczba chorych z dysfunkcją serca sięga już prawie 10 mln, a w Polsce znacznie przekracza 0,5 mln. Niewydolność serca jest zespołem klinicznym, cechuj...